GDNF in treatment of Parkinson's disease: response to editorial.
作者信息
Penn Richard D, Dalvi Arif, Slevin John, Young Byron, Gash Don, Gerhardt Greg, Hutchinson Michael
出版信息
Lancet Neurol. 2006 Mar;5(3):202-3. doi: 10.1016/S1474-4422(06)70360-X.
Abstract
摘要
相似文献
1
GDNF in treatment of Parkinson's disease: response to editorial.胶质细胞源性神经营养因子治疗帕金森病：对社论的回应
Lancet Neurol. 2006 Mar;5(3):202-3. doi: 10.1016/S1474-4422(06)70360-X.
2
GDNF in treatment of Parkinson's disease: response to editorial.胶质细胞源性神经营养因子治疗帕金森病：对社论的回应
Lancet Neurol. 2006 Mar;5(3):200-2. doi: 10.1016/S1474-4422(06)70359-3.
3
Continuing trials of GDNF in Parkinson's disease.胶质细胞源性神经营养因子治疗帕金森病的持续试验。
Lancet Neurol. 2006 Apr;5(4):285-6. doi: 10.1016/S1474-4422(06)70386-6.
4
Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?胶质细胞源性神经营养因子的封装细胞生物递送：帕金森病神经保护和神经再生的一种新临床策略？
Exp Neurol. 2008 Jan;209(1):82-8. doi: 10.1016/j.expneurol.2007.08.019. Epub 2007 Sep 14.
5
Reply: GDNF poses troubling questions for doctors, drug maker.回复：胶质细胞源性神经营养因子给医生和制药商带来了棘手的问题。
Ann Neurol. 2006 Jun;59(6):989-90. doi: 10.1002/ana.20880.
6
The hard way to a Bill of Rights.通往权利法案的艰难之路。
Lancet Neurol. 2005 Dec;4(12):787. doi: 10.1016/S1474-4422(05)70228-3.
7
Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.胶质细胞源性神经营养因子（GDNF）治疗帕金森病。
Acta Med Okayama. 2007 Apr;61(2):51-6. doi: 10.18926/AMO/32888.
8
GDNF therapy for Parkinson's disease.用于帕金森病的胶质细胞源性神经营养因子疗法。
Expert Rev Neurother. 2008 Jul;8(7):1125-39. doi: 10.1586/14737175.8.7.1125.
9
MRI volumetric and intensity analysis of the cerebellum in Parkinson's disease patients infused with glial-derived neurotrophic factor (GDNF).对注入胶质细胞源性神经营养因子（GDNF）的帕金森病患者小脑进行MRI容积和强度分析。
Exp Neurol. 2006 Apr;198(2):450-6. doi: 10.1016/j.expneurol.2005.12.021. Epub 2006 Feb 7.
10
Neurotrophic factor therapy for Parkinson's disease.神经营养因子治疗帕金森病。
Prog Brain Res. 2010;184:237-64. doi: 10.1016/S0079-6123(10)84013-0.
引用本文的文献
1
Physical Exercise and Health: A Focus on Its Protective Role in Neurodegenerative Diseases.体育锻炼与健康：聚焦其在神经退行性疾病中的保护作用
J Funct Morphol Kinesiol. 2022 Apr 29;7(2):38. doi: 10.3390/jfmk7020038.
2
Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson's Disease. A Systematic Review.帕金森病中由NR4A2（NURR1）转录因子减少所主导的临床试验中胶质细胞源性神经营养因子（GDNF）的失败。一项系统评价。
Front Aging Neurosci. 2021 Feb 24;13:645583. doi: 10.3389/fnagi.2021.645583. eCollection 2021.
3
Neuroregeneration in Parkinson's Disease: From Proteins to Small Molecules.帕金森病的神经再生：从蛋白质到小分子。
Curr Neuropharmacol. 2019;17(3):268-287. doi: 10.2174/1570159X16666180905094123.
4
Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications.基因治疗帕金森病：生物制剂的性质拓展了未来的适应证。
Pharmaceuticals (Basel). 2012 Jun 4;5(6):553-90. doi: 10.3390/ph5060553.
5
Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system.评估基于 AAV2 的雷帕霉素调控的胶质细胞源性神经营养因子（GDNF）表达载体系统。
PLoS One. 2011;6(11):e27728. doi: 10.1371/journal.pone.0027728. Epub 2011 Nov 21.
6
Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.帕金森病治疗学：左旋多巴问世以来的新进展和挑战。
Neuropsychopharmacology. 2012 Jan;37(1):213-46. doi: 10.1038/npp.2011.212. Epub 2011 Sep 28.
7
Ethical issues in clinical neuroscience research: a patient's perspective.临床神经科学研究中的伦理问题：患者视角
Neurotherapeutics. 2007 Jul;4(3):537-44. doi: 10.1016/j.nurt.2007.04.008.
Zotero 插件